In my recent exploration, I've found that sofosbuvir has significantly impacted the treatment disparities and access to care for hepatitis C patients. This revolutionary drug has proven to be a game changer, offering a cure to many suffering from this disease. Yet, despite its effectiveness, access to sofosbuvir remains unequal, mainly due to its high cost. This has led to significant disparities in treatment accessibility, particularly affecting low-income and uninsured individuals. So, while sofosbuvir has the potential to eradicate hepatitis C, its impact is currently limited by these challenges.
